Drug Trial Radar · NCT07814404
A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Sep 18, 2026
Primary completion
Oct 15, 2026
Study completion Oct 15, 2026
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is conducted to assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of \[14C\]-INCB161734 in healthy male participants.
Conditions
- Healthy Participants
Interventions
INCB161734Drug
Participants will be administered orally a dose solution consisting of INCB161734 and radiolabeled INCB161734.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Recovery (Urine + Feces) of the Administered RadioactivityTime frame: Up to 2 weeks
- Percentage of total radioactive dose in Plasma, Urinary and Fecal ExcretionTime frame: Up to 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Inc
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.